Myocardial Fibrosis - Pipeline Review, H2 2017

  • ID: 4436063
  • Drug Pipelines
  • 85 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Evotec AG
  • Galectin Therapeutics Inc
  • Invivosciences Inc
  • MandalMed Inc
  • Merck & Co Inc
  • Miragen Therapeutics Inc
  • MORE
Myocardial Fibrosis - Pipeline Review, H2 2017

Summary

The latest Pharmaceutical and Healthcare disease pipeline guide Myocardial Fibrosis - Pipeline Review, H2 2017, provides an overview of the Myocardial Fibrosis (Cardiovascular) pipeline landscape.

Myocardial fibrosis is an abnormal thickening of the heart valves due to inappropriate proliferation of cardiac fibroblasts. Symptoms include chest pain, some abdominal swelling, nausea and fatigue.

Report Highlights

The latest Pharmaceutical and Healthcare latest pipeline guide Myocardial Fibrosis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Myocardial Fibrosis (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Myocardial Fibrosis (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Myocardial Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies / Universities / Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 10 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.

Myocardial Fibrosis (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Myocardial Fibrosis (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Myocardial Fibrosis (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Myocardial Fibrosis (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Myocardial Fibrosis (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Myocardial Fibrosis (Cardiovascular).
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Myocardial Fibrosis (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Myocardial Fibrosis (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Evotec AG
  • Galectin Therapeutics Inc
  • Invivosciences Inc
  • MandalMed Inc
  • Merck & Co Inc
  • Miragen Therapeutics Inc
  • MORE
Introduction

Myocardial Fibrosis - Overview

Myocardial Fibrosis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Myocardial Fibrosis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Myocardial Fibrosis - Companies Involved in Therapeutics Development

Daewoong Pharmaceutical Co Ltd

Evotec AG

Galectin Therapeutics Inc

Invivosciences Inc

Lead Discovery Center GmbH

MandalMed Inc

Merck & Co Inc

Miragen Therapeutics Inc

Palatin Technologies Inc

ProMetic Life Sciences Inc

Sarfez Pharmaceuticals Inc

TRACON Pharmaceuticals Inc

Myocardial Fibrosis - Drug Profiles

BMP-7 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

carotuximab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drugs for Tissue Fibrosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DWN-10290 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GRMD-02 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Inhibit Marinobufagenin for Cardiovascular Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MRG-201 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NM-922 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PBI-4050 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PL-5028 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PN1-Ab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Inhibit Galectin-3 for Myocardial Fibrosis and Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small molecules to Inhibit CYP11B2 for Cardiovascular Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit RhoGEF12 for Cardiovascular Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SP-20102 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides to Agonize AGTR2 for Kidney Fibrosis, Liver Fibrosis and Myocardial Fibrosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TPI-2049 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TRC-205 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VB-0004 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Myocardial Fibrosis - Dormant Projects

Myocardial Fibrosis - Product Development Milestones

Featured News & Press Releases

Oct 29, 2015: ProMetic's PBI-4050 Cleared to Commence Clinical Trial in Patients With Type 2 Diabetes and Multi-Organ Fibrosis in Europe

Aug 05, 2014: Galectin Therapeutics Receives U.S. Patent for GR-MD-02 Composition of Matter

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Myocardial Fibrosis, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Myocardial Fibrosis - Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2017

Myocardial Fibrosis - Pipeline by Evotec AG, H2 2017

Myocardial Fibrosis - Pipeline by Galectin Therapeutics Inc, H2 2017

Myocardial Fibrosis - Pipeline by Invivosciences Inc, H2 2017

Myocardial Fibrosis - Pipeline by Lead Discovery Center GmbH, H2 2017

Myocardial Fibrosis - Pipeline by MandalMed Inc, H2 2017

Myocardial Fibrosis - Pipeline by Merck & Co Inc, H2 2017

Myocardial Fibrosis - Pipeline by Miragen Therapeutics Inc, H2 2017

Myocardial Fibrosis - Pipeline by Palatin Technologies Inc, H2 2017

Myocardial Fibrosis - Pipeline by ProMetic Life Sciences Inc, H2 2017

Myocardial Fibrosis - Pipeline by Sarfez Pharmaceuticals Inc, H2 2017

Myocardial Fibrosis - Pipeline by TRACON Pharmaceuticals Inc, H2 2017

Myocardial Fibrosis - Dormant Projects, H2 2017

List of Figures

Number of Products under Development for Myocardial Fibrosis, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Daewoong Pharmaceutical Co Ltd
  • Evotec AG
  • Galectin Therapeutics Inc
  • Invivosciences Inc
  • Lead Discovery Center GmbH
  • MandalMed Inc
  • Merck & Co Inc
  • Miragen Therapeutics Inc
  • Palatin Technologies Inc
  • ProMetic Life Sciences Inc
  • Sarfez Pharmaceuticals Inc
  • TRACON Pharmaceuticals Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll